Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03128996 · ClinicalTrials.gov registry record · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
A Phase 1 study of Hemoglobinopathies and Metabolic Disorders, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 4
- Study locations
NCT03128996 is a Phase 1 study of Hemoglobinopathies and Metabolic Disorders that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 29 participants, below the 1,802-participant average among 17 other Hemoglobinopathies trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT03128996, a Phase 1 study of Hemoglobinopathies and Metabolic Disorders, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is designed to estimate the efficacy and toxicity of familial HLA mismatched bone marrow transplants in patients with non-malignant disease who are less than 21 years of age and could benefit from the procedure.
Conditions Studied
Interventions
- DRUG RIC regimen
- DRUG GVHD prophylaxis regimen
Study Locations (4)
Connecticut
- Yale School of Medicine - New Haven
Delaware
- Nemours Children's Health - Wilmington
Michigan
- Helen DeVos Children's Hospital - Grand Rapids
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2017-03-20 |
| Est. Completion | 2033-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03128996
The ClinicalTrials.gov registry entry for NCT03128996 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,802-participant average among 17 other Hemoglobinopathies trials with a reported enrollment target (98% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Hemoglobinopathies appearing as the primary indexed condition, and to 2 interventions - of which RIC regimen is the first listed.
NCT03128996 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Connecticut, Delaware, Michigan.
Frequently Asked Questions
What is clinical trial NCT03128996 about?
NCT03128996 is a clinical study titled "Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders". This study is designed to estimate the efficacy and toxicity of familial HLA mismatched bone marrow transplants in patients with non-malignant disease who are less than 21 years of age and could benefit from the procedure.
What is the current status of trial NCT03128996?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2017-03-20. Estimated completion is 2033-04.
What conditions does trial NCT03128996 study?
This clinical trial studies the following conditions: Hemoglobinopathies, Metabolic Disorders, Bone Marrow Failure Syndromes, Non-malignant Disorders, Severe Sickle Cell Disease.
What interventions are being tested in trial NCT03128996?
The interventions under investigation include: RIC regimen (DRUG), GVHD prophylaxis regimen (DRUG).
Who is sponsoring clinical trial NCT03128996?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03128996 being conducted?
This trial has 4 study locations across Connecticut, Delaware, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemoglobinopathies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
RECRUITING · Phase 1
-
A Blood Stem Cell Transplant for Sickle Cell Disease
ACTIVE NOT RECRUITING · Phase 1
-
A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)
ACTIVE NOT RECRUITING · Phase 1
-
EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)
ACTIVE NOT RECRUITING · Phase 1
-
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
COMPLETED · Phase 1
-
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.